S
Shenzhen Huixin Biomedical Technology
Developing automated exosome purification systems for early cancer diagnosis and treatment applications
About Shenzhen Huixin Biomedical Technology
Shenzhen Huixin Biomedical Technology Co., Ltd. is a biotechnology company that develops automated systems for exosome purification, with applications in early disease detection, diagnostics, and biomedical research. The company's focus is on improving the efficiency and consistency of isolating exosomes—small extracellular vesicles found in biological fluids that carry molecular information such as proteins and nucleic acids.
HuixinBio’s purification platforms are designed to support workflows in clinical laboratories, academic research, and pharmaceutical development. These systems use microfluidic and automation technologies to streamline the exosome isolation process, aiming to provide high-purity samples while reducing manual handling and processing time.
The company's technology supports non-invasive diagnostic approaches such as liquid biopsy, which is used in areas like early cancer screening and biomarker discovery. By enabling more consistent and scalable exosome extraction, HuixinBio contributes tools that may assist in research and development for precision medicine and disease monitoring.
In addition to product development, Huixin Biomedical is engaged in partnerships and collaborations with institutions and researchers in the field of exosome science. The company continues to expand its portfolio to meet the needs of evolving biomedical and clinical applications.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Ningbo, China
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Biomedical, Precision Medicine, Health Diagnostics, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
Knowledge graph
News
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2025 | $14M | $55M | HaoYue Capital | ↗ |
| EARLY VC✓Equity / VC | Jan 2023 | $2.8M | $11M | South China Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Shenzhen Huixin Biomedical Technology is 950 monthly website visits, up 156.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shenzhen Huixin Biomedical Technology in the Ningbo ecosystem
The Shenzhen Huixin Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
South China Venture Capital
HaoYue Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shenzhen Huixin Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shenzhen Huixin Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.